Ifinatamab Deruxtecan for Esophageal Cancer

This trial examines whether a new treatment, ifinatamab deruxtecan (I-DXd), can help individuals with esophageal squamous cell carcinoma (ESCC), a type of esophageal cancer. I-DXd targets cancer cells, delivering treatment directly to them to shrink or eliminate the cancer. The trial seeks participants whose ESCC has worsened despite one or two prior treatments. Eligible participants should have a type of ESCC that cannot be surgically removed and should not have other major health issues that could interfere with the trial. As a Phase 1, Phase 2 trial, this research aims to understand how the treatment works in people and measure its effectiveness in an initial, smaller group, offering participants a chance to be among the first to benefit from this innovative therapy.

The trial information does not specify if you need to stop taking your current medications. However, if you have an active infection requiring systemic therapy, it might not be allowed. It's best to discuss your specific medications with the trial team.

Research has shown that ifinatamab deruxtecan (I-DXd) is generally safe to use, with side effects typically being mild and manageable with proper care. In earlier studies, some patients responded well to I-DXd, with the treatment helping to shrink tumors in those who had already undergone multiple treatments. Although side effects occurred, they were considered manageable. This suggests that the treatment is relatively safe, though individual experiences may vary.¹²³⁴⁵

Most treatments for esophageal cancer, like chemotherapy and radiation, work by attacking rapidly dividing cancer cells, but they can also harm healthy cells. Ifinatamab Deruxtecan (I-DXd) is unique because it targets cancer cells more precisely, using an antibody-drug conjugate that binds to specific proteins on the cancer cells before delivering a potent chemotherapy agent directly to them. This targeted approach minimizes damage to healthy cells and may lead to fewer side effects. Researchers are excited about I-DXd because its targeted mechanism shows promise for more effective treatment outcomes with potentially improved safety.

Research has shown that ifinatamab deruxtecan (I-DXd), a targeted cancer treatment, may help treat esophageal squamous cell carcinoma (ESCC). In earlier studies with a similar cancer, over half of the patients experienced tumor shrinkage, with a 54.8% response rate. This treatment targets a specific protein on cancer cells and delivers a drug to destroy them. Participants in this trial will receive I-DXd every three weeks until they meet criteria for progressive disease or discontinuation. These findings suggest that I-DXd could shrink or eliminate ESCC in some patients.²³⁶⁷⁸